Insider Worth Mentioning: Carl Lebel Sold $192,006 Worth of Otonomy Inc (NASDAQ:OTIC) Stock

November 23, 2016 - By Darrin Black

Insider Worth Mentioning: Carl Lebel Sold $192,006 Worth of Otonomy Inc (NASDAQ:OTIC) Stock

Carl Lebel Insider Sell

Mr. Carl Lebel, the acting Chief Scientific Officer at Otonomy Inc has a few days ago been connected with a stock market sale of 10,625 shares of the California-based company, valued at $18.1 per share. The deal value was of $192,006 U.S Dollars. Now, he has in hand 9,458 shares or 0.03% of Otonomy Inc’s market cap (total dollar market value of all company’s outstanding shares). Dated November 22, 2016 the transaction document is freely available here.

Otonomy Inc (NASDAQ:OTIC) Ratings Coverage

Out of 2 analysts covering Otonomy (NASDAQ:OTIC), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Otonomy has been the topic of 3 analyst reports since August 10, 2015 according to StockzIntelligence Inc. The stock of Otonomy Inc (NASDAQ:OTIC) earned “Hold” rating by JP Morgan on Thursday, August 13. Bernstein upgraded Otonomy Inc (NASDAQ:OTIC) on Monday, August 10 to “Outperform” rating. The rating was initiated by WallachBeth Capital on Thursday, May 26 with “Buy”.

Insitutional Activity: The institutional sentiment decreased to 1.29 in 2016 Q2. Its down 0.19, from 1.48 in 2016Q1. The ratio dived, as 13 funds sold all Otonomy Inc shares owned while 18 reduced positions. 7 funds bought stakes while 39 increased positions. They now own 25.98 million shares or 0.23% less from 26.04 million shares in 2016Q1.

Jpmorgan Chase And Company holds 0% of its portfolio in Otonomy Inc (NASDAQ:OTIC) for 5,010 shares. Millennium Mgmt Lc owns 796,836 shares or 0.03% of their US portfolio. Columbus Circle Invsts holds 0% or 28,666 shares in its portfolio. Ubs Oconnor Ltd Limited Liability Company last reported 0% of its portfolio in the stock. Citigroup reported 3,648 shares or 0% of all its holdings. Tower Capital Llc (Trc) accumulated 0% or 1,315 shares. Fil Limited has 61,671 shares for 0% of their US portfolio. Fred Alger accumulated 23,150 shares or 0% of the stock. Northern Tru last reported 0% of its portfolio in the stock. Swiss Commercial Bank accumulated 0% or 32,100 shares. Vanguard Group Inc has invested 0% of its portfolio in Otonomy Inc (NASDAQ:OTIC). Bnp Paribas Arbitrage Sa holds 0% of its portfolio in Otonomy Inc (NASDAQ:OTIC) for 949 shares. Everpoint Asset Mngmt Ltd reported 300,000 shares or 0.09% of all its holdings. Geode Cap Mgmt Llc accumulated 0% or 170,819 shares. Proshare Limited Com last reported 0.01% of its portfolio in the stock.

Insider Transactions: Since September 6, 2016, the stock had 0 insider purchases, and 1 sale for $381,438 net activity. $381,438 worth of Otonomy Inc (NASDAQ:OTIC) was sold by LeBel Carl.

The stock decreased 0.83% or $0.15 during the last trading session, hitting $17.95. About 66,156 shares traded hands. Otonomy Inc (NASDAQ:OTIC) has risen 8.06% since April 20, 2016 and is uptrending. It has outperformed by 3.50% the S&P500.

Otonomy, Inc. is a biopharmaceutical company. The company has a market cap of $541.99 million. The Firm focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. It currently has negative earnings. The Firm has developed a technology referred to as sustained-exposure that is designed to deliver drug that is retained in the ear for an extended period of time following a local administration.

According to Zacks Investment Research, “Otonomy, Inc. engages in developing and commercializing therapeutics to address unmet medical needs in the otology market. It develops therapeutics for treatment of inner and middle ear disorders. The Company’s product candidates under development includes AuriPro to treat pediatric patients with middle ear effusion; and OTO-104 for the treatment of patients with Ménière’s disease. Otonomy, Inc. is headquartered in San Diego, California.”

More recent Otonomy Inc (NASDAQ:OTIC) news were published by: Globenewswire.com which released: “Otonomy to Present at Piper Jaffray Healthcare Conference” on November 22, 2016. Also Globenewswire.com published the news titled: “Otonomy Announces FDA Approval of OTIPRIO(TM) for the Treatment of Pediatric ..” on December 11, 2015. Globenewswire.com‘s news article titled: “Otonomy to Host Investor and Analyst Day on October 7, 2016” with publication date: September 29, 2016 was also an interesting one.

OTIC Company Profile

Otonomy, Inc., incorporated on May 6, 2008, is a biopharmaceutical company. The Firm focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Firm has developed a technology referred to as sustained-exposure that is designed to deliver drug that is retained in the ear for an extended period of time following a local administration. The Company’s product candidates include OTIPRIO, OTO-104 and OTO-311.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>